Single-blinded, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are:
* Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile?
* What medical problems do participants experience while taking the treatment?
Participants will:
* Take the treatment described according to the Summary of Product Characteristics (SmPC).
* Visit the clinic once every 12 weeks for checkups and tests.
* Keep a diary of their symptoms to inform the Investigator.

Start Date01 Apr 2025

Sponsor / Collaborator-

ChiCTR2500098958

/ SuspendedNot ApplicableIIT

Targeted GLP-1R PET imaging in the clinical application of endogenous hyperinsulinemia

Start Date18 Mar 2025

Sponsor / Collaborator-

ACTRN12624001245583

/ Not yet recruitingEarly Phase 1IIT

SUBDUE-3: A Phase 0 study of SUB-urothelial DUrvalumab-Zirconium to investigate local and systemic distribution of Durvalumab when injected in the sub-urothelium of adult subjects with muscle invasive bladder cancer or high-risk non-muscle invasive bladder cancer

Start Date10 Feb 2025

Sponsor / Collaborator-

100 Clinical Results associated with Dulaglutide

100 Translational Medicine associated with Dulaglutide

100 Patents (Medical) associated with Dulaglutide

1,303

Literatures (Medical) associated with Dulaglutide

01 Jun 2025·NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders

Review

Author: Lam, Pak Ho ; Au, Hezekiah C T ; McIntyre, Roger S ; Lim, Poh Khuen

INTRODUCTION:

Glucagon-like Peptide-1 (GLP-1) and Glucagon-Like Peptide-1 receptor agonist (GLP-1 RA) administration has been associated with neuroprotective effects in neurodegenerative disorders. We conducted a comprehensive synthesis of known effects of GLP-1 and GLP-1 RAs on the cognitive, cellular, and molecular changes in neurodegenerative diseases.

METHODS:

We examined preclinical and clinical paradigms that investigated changes in neurodegenerative disease pathology following administration of GLP-1 and GLP-1 RAs. Relevant articles were retrieved through OVID (MedLine, Embase, AMED, PsychINFO, JBI EBP Database), PubMed, and Web of Science from database inception to September 27th, 2024. Primary studies investigating the aforementioned changes following GLP-1 and GLP-1 RA administration were retrieved for analysis (n = 62).

RESULTS:

GLP-1 and GLP-1 RAs (i.e. dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide) improved cognitive and motor function in neurodegenerative diseases in preclinical and clinical paradigms. Additionally, GLP-1 and GLP-1 RAs were associated with modulating changes in neuroinflammation, oxidative stress, and proliferative pathways.

DISCUSSION:

We observed that GLP-1 and GLP-1 RAs modulate molecular and cellular changes known to govern the phenomenology of neurodegenerative diseases. Future research should examine the interaction between signaling molecules, neuronal subpopulations, and cognitive effects affected by GLP-1 and GLP-1 RA administration.

01 May 2025·BRITISH JOURNAL OF ANAESTHESIA

Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system

Article

Author: Liu, Fan ; Huang, Haoquan ; Fu, Yanni ; Hu, Chuwen ; Cao, Minghui ; Ji, Fengtao

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) potentially increase the risk of pulmonary aspiration resulting from impaired gastric emptying (IGE). We evaluated the association between GLP-1RAs and IGE using the US Food and Drug Administration Adverse Event Reporting System (FAERS).

METHODS:

We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use. Disproportionality analysis using the reporting odds ratio was conducted to assess the relative IGE risk for each drug. Logistic regression analysed the impact of age, weight, and sex on IGE risk. Cumulative incidence and time to onset of IGE events were examined using Kaplan-Meier and Weibull shape parameter tests.

RESULTS:

Among the top 10 drugs associated with IGE reports, five were GLP-1RAs, accounting for 49.5% (982/1982) of cases. Dulaglutide (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.94-1.00, P=0.033) and semaglutide (OR 0.96, 95% CI 0.94-0.97, P=0.001) showed lower IGE risk with older age. For exenatide, higher weight (OR 0.99, 95% CI 0.98-1.00, P=0.033) and male sex (OR 0.39, 95% CI 0.20-0.68, P=0.033) were associated with lower IGE risk. Median onset times ranged from 40.5 days (semaglutide) to 107.5 days (tirzepatide) from intitiation of therapy. The Weibull shape parameter β was <1 for all GLP-1RAs, indicating a higher IGE risk early in treatment.

CONCLUSIONS:

GLP-1RAs were notably associated with reports of impaired gastric emptying in the FAERS. Age, weight, and sex were significantly associated with impaired gastric emptying risk for certain GLP-1RAs. IGE events tended to occur early in treatment, with risk diminishing over time. These findings provide valuable references for future research on perioperative safety with GLP-1RAs.

01 May 2025·Diabetes Therapy

Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise

Article

Author: Li, Yijun ; Zou, Huimin ; Ni, Qi ; Mu, Yiming ; Ung, Carolina Oi Lam ; Chen, Xianwen ; Zhang, Hao ; Hu, Ying ; Hu, Hao ; Shen, Yang

INTRODUCTION:

This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.

METHODS:

This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg. It was performed from the perspective of the Chinese healthcare systems over a 40-year time horizon, with an annual discount rate of 5%. Baseline cohort characteristics and treatment effects were sourced from the head-to-head clinical trial SUSTAIN 7, which compared the efficacy and safety of semaglutide and dulaglutide. The analysis included direct medical costs regarding antidiabetic treatment and complication treatment. The long-term cost-effectiveness analysis used quality-adjusted life years (QALYs) as the primary health outcome. The robustness of the results was evaluated through one-way sensitivity analyses and probabilistic sensitivity analyses. The short-term cost-effectiveness analysis, focusing on the proportion of patients achieving clinical targets as the health outcome, compared the control costs of successfully treating a patient to meet clinical treatment goals between semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg over a 40-week study period.

RESULTS:

Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY. Sensitivity analyses confirmed the robustness of these results. In the short-term cost-of-control study, once-weekly semaglutide 0.5 mg demonstrated lower treatment costs for all targets: the costs of control for dulaglutide 1.5 mg were 1.2-2.1 times as much as that of semaglutide 0.5 mg once weekly. Semaglutide 1.0 mg achieved similar treatment costs for the good glycemic control goal (HbA_1c < 7%) to dulaglutide 1.5 mg. However, when looking at tight glycemic control, weight management targets, and composite targets relating to weight loss, once-weekly semaglutide 1.0 mg showed lower treatment costs compared to dulaglutide 1.5 mg to bring at least one patient to achieve these targets.

CONCLUSIONS:

Compared to dulaglutide 1.5 mg, once-weekly semaglutide remains cost-effective for treating type 2 diabetes uncontrolled on metformin in China under the new negotiation price. However, limitations exist, including the reliance on SUSTAIN-7 data and the lack of specific utility data for the Chinese population.

433

News (Medical) associated with Dulaglutide

02 May 2025

·www.globenewswire.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHIV 2025), taking place May 1-3 in Chicago, Ill. Both presentations focus on issues surrounding excess visceral abdominal fat (EVAF), a common comorbidity in people with HIV (PWH). One poster presents a new analysis of data from the Visceral Adiposity Measurement and Observations Study (VAMOS), in which EVAF was associated with reduced muscle quality in aging PWH. VAMOS is the first trial designed to improve the understanding of the impact of EVAF on cardiovascular disease, steatotic liver disease, insulin resistance, and other metabolic parameters in PWH. The second presentation reports on a first-of-its-kind case series in which the combination of tesamorelin and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy was highly effective in reducing both EVAF and obesity in a real-world setting. “We are proud to continue our exploration into the complexities of excess visceral abdominal fat in people with HIV,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. “As people with HIV live longer, analyses such as the data we are presenting at ACTHIV are critical to addressing this population’s evolving health needs. Our research adds to the growing understanding that body composition, most importantly EVAF, is a key factor in aging-related functional decline in HIV, and we are committed to investigating this complex relationship.” VAMOS Analysis Poster Title: Reduced Muscle Quality is Highly Prevalent in Aging People with HIV (PWH) and is Associated with Excess Visceral Abdominal Fat (EVAF) First Author: Zachary Henry, DO, AIDS Healthcare Foundation, Fort Lauderdale, Fla. In the latest analysis from the multicenter VAMOS study, researchers investigated how EVAF, compared to subcutaneous fat, is associated with muscle quality in PWH on modern anti-retroviral regimens, and explored potential drivers of this relationship. Among the 170 participants, EVAF prevalence was 58%. Muscle quality was found to be lower with increasing age of participants (r= -0.465; p<0.0001), but was not significantly correlated with body mass index (BMI) (r= -0.118; p=0.124). EVAF was associated with lower skeletal muscle quality, as demonstrated by lower muscle mean attenuation (r= -0.445; p<0.0001). The researchers concluded that increased levels of visceral fat – more so than subcutaneous fat or increasing BMI – strongly correlate with reduced skeletal muscle quality, which may amplify age-related functional declines. Tesamorelin/GLP-1 RA Case Series Poster Title: High Levels of Treatment Success Seen with Combined Use of Tesamorelin and GLP1-RAs in People with HIV First Author: Daniel Lee, MD, University of California San Diego Department of Medicine, San Diego, Calif. In the case series, investigators reported on the real-world use of tesamorelin for the treatment of EVAF in PWH, in combination with GLP-1 RAs, which are commonly used for diabetes and obesity management in the general population. Among the seven PWH evaluated in the case series, tesamorelin was initiated first in all cases to address EVAF, with a mean reduction in waist circumference of 1.3 inches. The principal reasons for adding a GLP-1-RA included improving BMI and diabetic control. Following at least six months of combination therapy, patients saw mean reductions in weight (-13 pounds), BMI (-2.2 kg/m2), and waist circumference (-3.4 inches), with six of the seven patients achieving their metabolic and body composition goals. Combination therapy is ongoing in most of the patients (6/7). This is the first known report of the dual use of these agents in PWH, highlighting their complementary but distinct mechanisms of action. “The combination of tesamorelin and GLP-1 medications represents a new frontier in metabolic care for people with HIV,” noted Dr. Marsolais. “By distinguishing between and targeting both excess visceral abdominal fat and generalized obesity, treatment strategies can be tailored to address the specific needs of people living with HIV.” Both posters can be found at www.theratech.com and www.acthiv.org following the conference. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on LinkedIn and X. Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "should", "could", “promising”, “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the Company’s commitment to investigate the relationship between body composition and aging and the tailoring of treatment strategies for PWH. Forward-looking statements involve a number of assumptions, risks and uncertainties. Some of these assumptions include, but are not limited to, the duration of treatment and the responses to the administered drugs by PWH. Some of the risks include that PWH may not respond similarly when they take medicines and results may differ from what those were observed and reported through VAMOS and the tesamorelin/GLP-1 RA case series. The Company refers current and potential investors to the “Risk Factors” section of the Company’s Annual Information Form filed on Form 20-F dated February 26, 2025 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings for the risks associated with the business of Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com514-336-7800 Investor Inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com551-261-0401

Clinical Result

15 Apr 2025

·www.globenewswire.com

CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, today announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) for a U.S. Phase 2 trial of CX11, an investigational oral once-daily small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). This randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of CX11 in patients with obesity and overweight conditions in the U.S., with enrollment expected to begin in the second quarter of 2025. CX11 (also known as “VCT220”), for which CORXEL acquired global ex-China rights from Suzhou Vincentage Pharma Co., Ltd (Vincentage) in December 2024, is a once-daily oral product candidate designed to offer a convenient alternative to injectable GLP-1 treatments. In a previous Phase 2 trial conducted by Vincentage in China, CX11 achieved competitive weight loss with favorable safety and tolerability. CORXEL’s U.S. Phase 2 trial targets to enroll 250 patients, including those with a BMI of ≥30 kg/m² or a BMI of ≥27 kg/m² with at least one weight-related comorbidity, to receive treatment over 36 weeks and to be further monitored over a 2-week follow-up period. Topline data from this trial is expected in the first half of 2026, and if positive, would pave the way for a global Phase 3 development. CORXEL’s partner Vincentage initiated a Phase 3 registrational obesity trial in China in November 2024. “We are excited to receive the Study May Proceed Letter from the FDA for the U.S. Phase 2 trial of CX11, a critical milestone in our mission to address the global burden of obesity and related cardiometabolic diseases,” said Bo Liang, Senior Vice President, Head of Clinical Development – Metabolic at CORXEL. “Currently approved GLP-1 therapies, while generally effective, often face obstacles such as weekly injections, titration difficulty, side effects and limited tolerability, maintaining weight loss and supply challenges for peptide-based therapies. With once-daily oral administration and promising clinical data, CX11 aims to address these issues, potentially offering a best-in-class convenient oral treatment solution for patients globally.” About CX11 CX11 is an investigational oral small molecule GLP-1 RA designed to address cardiometabolic conditions, with a primary focus on obese and overweight patients. With global ex-China rights acquired by CORXEL from Vincentage in December 2024, CX11 aims to overcome limitations of current injectable GLP-1 RAs by offering convenient, once-daily oral administration, weight reduction comparable to injectable GLP-1 RAs, favorable tolerability results, scalability and accessibility as a small molecule product candidate. Clinical data from Vincentage’s Phase 2 trial in China demonstrated competitive weight loss with a favorable safety and tolerability profile. CX11 is currently advancing into a U.S. Phase 2 trial by CORXEL and through a Phase 3 registrational trial in China conducted by Vincentage, positioning it as a potential best-in-class oral therapy for management of obesity and overweight conditions. About CORXEL’s U.S. Phase 2 Clinical Trial for CX11 CX11’s U.S. Phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial, designed to assess the efficacy and safety profile of CX11 in individuals with obesity and overweight in the United States. The trial targets to enroll 250 patients, including those with a BMI of ≥30 kg/m² or a BMI of ≥27 kg/m² with at least one weight-related comorbidity. The trial will feature five treatment arms: four active treatment groups receiving 120 mg, 160 mg, 200 mg with fast titration, 200 mg with slow titration, of CX11, as well as a placebo group. Patients will receive treatment for 36 weeks and will be further monitored over a 2-week follow-up period. Topline data from this trial is expected to be released in the first half of 2026. About CORXEL CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world. CORXEL is led by an experienced management team that has a strong track record of identifying, in-licensing and developing attractive clinical product candidates directed at validated targets with proven mechanisms of action (MoAs). CORXEL’s diverse portfolio of clinical-stage product candidates has the potential to redefine treatment standards and address key limitations of current therapies for multiple cardiometabolic indications. CORXEL is developing selective small molecule compounds across the cardiometabolic spectrum with the lead product candidate CX11, an oral GLP-1 receptor agonist (GLP-1 RA) for obese and overweight patients, JX10, a thrombolytic and anti-inflammatory agent for acute ischemic stroke (AIS) and JX09, a highly selective aldosterone synthase inhibitor (ASI) for hypertension. For further information about CORXEL, please visit www.corxelbio.com   media@corxelbio.com

Phase 2INDClinical Result

04 Apr 2025

·www.prnewswire.com

ACP and Annals of Internal Medicine present breaking scientific news at ACP's Internal Medicine Meeting 2025

Authors discuss research on AI in the exam room, switching GLP1-RAs for better glucose and weight control, and ACP's best practice advice for the use of cannabis and cannabinoids for noncancer pain NEW ORLEANS, April 4, 2025 /PRNewswire/ -- Today at the American College of Physicians (ACP) annual meeting, Internal Medicine Meeting 2025, in New Orleans, Annals of Internal Medicine presented three breaking scientific research articles during a live plenary session featuring the authors of those articles. The articles were published in ACP's flagship journal concurrent with the live meeting presentation. Continue Reading "Sharing this research at our plenary and publishing it in Annals of Internal Medicine underscores its significance." Post this ACP and Annals of Internal Medicine present breaking scientific news at ACP’s Internal Medicine Meeting 2025. During the session, New in Annals of Internal Medicine: Hear it First from the Authors, Christine Laine, M.D., MPH, FACP Annals of Internal Medicine Editor-in-Chief and ACP Senior Vice President, interviewed each author to gain insight into their research. The articles presented were: Comparison of Initial Artificial Intelligence (AI) and Final Physician Recommendations in AI-Assisted Virtual Urgent Care Visits. Zehavi Horowitz-Kugler M.D., Vice President, Medical Sciences at K Health, Inc., discussed findings from a study comparing artificial intelligence (AI)-driven clinical recommendations to physician decision-making for common acute complaints in a virtual primary care setting. In the study, AI recommendations were largely rated as superior to physicians by expert adjudicators. According to Dr. Horowitz-Kugler, this is because AI is trained on a massive amount of high-quality, real-world clinical data, which is far beyond what any physician would see in their lifetime. Combined with human physician discernment, this approach could improve patient care and outcomes. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide. Liana K Billings, M.D., MMSc, Vice Chair of Research, Department of Medicine, Endeavor Health (NorthShore Hospitals), explained that for patients with inadequately controlled type 2 diabetes, switching to tirzepatide improves glucose control and increases weight loss more so than maximizing dulaglutide dose. This is important because delays in attaining at-goal glucose control can increase the risk and progression of diabetes-related complications, such as kidney disease and eye disease. Dr. Billings noted that adverse effects were similar in both groups. Cannabis or Cannabinoids for the Management of Chronic Noncancer Pain: Best Practice Advice From the American College of Physicians. Adam J. Obley, M.D., FACP Associate Professor of Medicine at Oregon Health & Science University and a member of ACP's Clinical Guidelines Committee, explained that ACP's Best Practice Advice paper is intended to inform clinicians about the evidence regarding the benefits and harms of cannabis or cannabinoids and to provide advice for clinicians counseling patients seeking to use cannabis or cannabinoids for chronic noncancer pain. ACP suggests that physicians counsel their patients about the benefits and harms of cannabis or cannabinoids when patients are considering whether to start or continue their use to manage chronic noncancer pain. ACP advised caution, as the harms of cannabis use may outweigh the benefits for some patients, especially young adults and adolescents, those with substance use disorder, or patients with serious mental health issues. Patients who are pregnant, breastfeeding or actively trying to conceive should be counseled against cannabis use. For all patients, ACP recommends against the use of inhaled cannabis. "Sharing this groundbreaking research at our plenary session and publishing it in Annals of Internal Medicine underscores its significance," said Dr. Laine. "These topics are relevant to internal medicine and primary care physicians and address issues commonly seen during the patient encounter. By giving physicians timely access to these scientific insights, we aim to improve care and enhance clinical practice." About the American College of Physicians The American College of Physicians is the largest medical specialty organization in the United States with members in more than 172 countries worldwide. ACP membership includes 161,000 internal medicine physicians, related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on X, Facebook, Instagram, Threads, and LinkedIn. About Annals of Internal Medicine Annals of Internal Medicine is the flagship journal of the American College of Physicians (ACP). Annals is the most widely read and cited general internal medicine journal and one of the most influential peer-reviewed clinical journals in the world. Annals' mission is to promote excellence in medicine, enable physicians and other health care professionals to be well-informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. New content is published every Tuesday at Annals.org. Follow Annals on X, Facebook, Instagram, Threads, and LinkedIn. SOURCE American College of Physicians WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Dulaglutide

External Link

KEGG	Wiki	ATC	Drug Bank
D09889	Dulaglutide	A10BJ05	DB09045

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	18 Sep 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoglycemia	Phase 3	Japan	Eli Lilly & Co.	13 Apr 2021
Chronic Kidney Diseases	Phase 3	United States	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Brazil	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Hungary	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Mexico	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Poland	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Romania	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	South Africa	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Spain	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Ukraine	Eli Lilly & Co.	01 Jul 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Ra-pacific (ESMO_ELCC2025)	Not Applicable	Non-small cell lung cancer stage III PD-L1 positive	42	Durvalumab	bjxhjvdkqb(gxwwrggukr) = dyricxzlgz fczmslcyqn (xqqchjrygt ) View more	Positive	26 Mar 2025
NCT03204396 (Pubmed \| Eur J Prev Cardiol)	Phase 2	Smoking Cessation	255	Dulaglutide 1.5mg	dkvpbaqisg(lfpgwcykkm) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation jjbwxhfngq (vhojjhqial )	-	03 Mar 2025
NCT05659537 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	212	Dulaglutide	rfgzviaovp = aysudcyafp mkaywdtasc (vzkuqlheny, gntdwxxgrg - wlumxrfule) View more	-	05 Feb 2025
TOPAZ-1 (ASCO_GI2025)	Not Applicable	Advanced biliary tract cancer	1,099	Durvalumab plus chemotherapy	hgcxlxdmri(sforbpxucb) = ysgfjdgtzs lbpcobsawe (xnoqnstvwp )	Positive	23 Jan 2025
TOPAZ-1 (ASCO_GI2025)	Not Applicable	Advanced biliary tract cancer	1,099	Chemotherapy only	hgcxlxdmri(sforbpxucb) = umynskrxrf lbpcobsawe (xnoqnstvwp )	Positive	23 Jan 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer First line	-	Durvalumab + Lenvatinib + Gemcitabine-based chemotherapy	kjpexrjbzy(iyhgzsehbu) = All patients experienced adverse events (AEs), addition of lenvatinib does not increase the risk of AEs dkynjtwabw (mtnthcajvl )	Positive	23 Jan 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer First line	-	Durvalumab + Gemcitabine-based chemotherapy		Positive	23 Jan 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer	50	Durvalumab plus gemcitabine and cisplatin	ekxeuqrfcr(qhkjtbfafl) = Most AEs were related to chemotherapy, there were 10% immune related AEs yhykbfjdgm (wyydhsuwwc )	Positive	23 Jan 2025
ACTRN12623000223639 (ASCO_GI2025)	Not Applicable	Advanced Pancreatic Ductal Adenocarcinoma	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	gowkyythsa(spobyfetbn) = xlmnmblvgx eafnwqxeok (wnrqmaaqmm )	Positive	23 Jan 2025
HIMALAYA (ASCO_GI2025)	Not Applicable	-	108	Durvalumab + Tremelimumab	llubdiatqh(lunjaagcka) = sabzczqaqg agxazdgtlm (bpjfqrlehy, 27.5 - 65.1) View more	Positive	23 Jan 2025
HIMALAYA (ASCO_GI2025)	Not Applicable	-	108	Durvalumab	siioteodlq(mfpaieawxm) = urvaemvszd vmsacshxyx (exmvpxmjkt, 6.0 - 12.1) View more	Positive	23 Jan 2025
NCT04862234 (CTgov)	Phase 4	Hyperglycemia	16	Continuous glucose monitor (CGM), blinded+Dulaglutide (Dulaglutide)	ppfknhapaw(cvbytxtowo) = tahyzylnoc kmmimfiskg (pxwnwntwik, 19.70) View more	-	17 Jan 2025
NCT04862234 (CTgov)	Phase 4	Hyperglycemia	16	Continuous glucose monitor (CGM), blinded (Placebo)	ppfknhapaw(cvbytxtowo) = gjszjfhisd kmmimfiskg (pxwnwntwik, 27.26) View more	-	17 Jan 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis